R Squared’s Denali Therapeutics DNLI Stock Holding History

R Squared’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-580	Closed	-$11.8K	–	620
2024 Q4	$11.8K	Buy	+580	New	+$14.8K	0.01%	1094

Other funds holding DNLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

R Squared's DNLI Position: Q1 2025 in Review

R Squared sold out of Denali Therapeutics (DNLI) in Q1 2025, closing a stake of 580 shares — an estimated $11.8K sold.

R Squared first reported a position in DNLI in Q4 2024 and held it in 1 quarter. The position peaked at $11.8K in Q4 2024. 222 funds tracked by Wall St. Rank hold DNLI as of Q1 2025.

R Squared reported no remaining Denali Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 580 Denali Therapeutics shares in Q1 2025, an estimated $11.8K.
R Squared first reported a position in Denali Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Denali Therapeutics position peaked at $11.8K in Q4 2024.
222 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.